METAP2 and obesity due to melanocortin 4 receptor deficiency: Inhibitors for human MetAP2 are well tolerated in patients at therapeutically relevant doses and have been developed for a variety of pharmaceutical applications, including the treatment of cancer [27,28,29,30,31], diabetes, and obesity [32], as well as the modulation of autoimmunity [33,34].